Posted on 16th December 2019 by bwarman

ASH 2019 - Our blood cancer research on an international stage

Once again this December, researchers from Barts Cancer Institute (BCI)’s Centre for Haemato-Oncology made the trip to the American Society of Hematology (ASH) Annual Meeting and Exposition, which this year took place in Orlando, Florida on 7th-10th December.

Members of BCI's Centre for Haemato-Oncolgy at the ASH Annual Meeting and Exposition 2019.

In its 61st year, this premier event in malignant and non-malignant haematology brings together more than 25,000 professionals from all subspecialties of haematology, and represents an invaluable opportunity for our researchers to highlight the work of BCI’s Centre for Haemato-Oncology on an international stage. The event is made up of a variety of sessions covering key topics from basic and clinical haematology research in the form of poster and oral presentations.

Professor John Gribben at ASH 2019.

This year was the first year that Professor John Gribben, Lead for BCI’s Centre for Haemato-Oncology, attended as President of the European Hematology Association (EHA). At the meeting, Professor Gribben co-chaired the ASH-EHA Joint Symposium which took place on 8th December. This session was focused on normal and malignant haematopoiesis, and looked at the links between specific metabolic pathways and the development of blood cancers.

Professor Gribben said:

"ASH was a very exciting meeting with a record of more than 30,000 attendees. This was a fantastic opportunity to highlight the research being performed by the staff of the Centre for Haemato-Oncology at Barts Cancer Institute."

Dr Okosun at ASH 2019.
Dr Jessica Okosun presenting at the TRTH Scientific Symposium at ASH 2019 on 8th December.

Training and mentoring for early-career haematological scientists 

This year marks the 10th anniversary of Translational Research Training in Hematology (TRTH), a programme created by EHA and ASH that provides junior researchers with a unique, year-long training and mentoring experience. The training programme is designed to help early-career haematological scientists build successful careers in leading translational haematology research.

In recognition of the 10th anniversary of TRTH, there was a special TRTH Scientific Symposium at this year’s ASH Annual Meeting and Exposition, which included talks from TRTH alumni. Dr Jessica Okosun, a clinician scientist and Group Leader in BCI’s Centre for Haemato-Oncology, was one of four speakers selected out of 200 alumni to present at this session.

Dr Okosun’s talk was entitled ‘Metabolic Perturbations in Follicular Lymphoma: Clues from the Genetics,’ and was about her research on the discovery of mutations in a gene called RRAGC in follicular lymphoma and the journey detailing the improved recognition of how genetic changes can shape the metabolic landscape of tumours.

Dr Okosun said:

"I was incredibly honoured to be selected out of such a stellar TRTH alumni to present at the anniversary. Hearing the accomplishments from past and present alumni is a real testament to the success of the TRTH programme, that has been instrumental in shaping my academic development. It is a fantastic lifelong community to be part of."

Other attendees from the Centre included Clinical Research Fellows Dr Joseph Taylor, Dr James Aries and Dr Robin Sanderson who gave oral presentations about their work. Postdoctoral Researchers Dr Findlay Copley and Dr Emily Saunderson, and PhD student Arantxa Romero-Toledo also presented posters this year to showcase their work.

Dr James Aries presenting at ASH 2019.
Dr James Aries presenting at ASH 2019 on 9th December. Talk entitled ‘Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT.’

Dr Robin Sanderson presenting at ASH 2019.
Dr Robin Sanderson presenting at ASH 2019 on 7th December. Talks entitled: '249 CAR T Cells Derived from Healthy Mice Lead to Cytokine Release Syndrome (CRS) in the TCL1 Chronic Lymphocytic Leukemia Model'; and 'Mice with CLL Treated with Acalabrutinib or Ibrutinib Have Improved CAR T Cell Function without Increasing the Cytokines of CRS'

Dr Findlay Copley at ASH 2019.
Dr Findlay Copley with his poster entitled 'Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel.’

Dr Joseph Taylor presenting at ASH 2019.
Dr Joseph Taylor presenting at ASH 2019 on 9th December. Talk entitled 'Beyond Exhaustion: The PDL1-PD1 Axis Shapes the Classical Hodgkin Lymphoma Microenvironment.'

Dr Emily Saunderson at ASH 2019.
Dr Emily Saunderson with her poster entitled 'CRISPR/Cas9-Targeted De Novo DNA Methylation Is Maintained and Impacts the Colony Forming Potential of Human Hematopoietic CD34+ Cells.'

Arantxa Romero Toledo at ASH 2019.
Arantxa Romero-Toledo with her poster at ASH 2019. Title: 'Treatment with Acalibrutinib, Ibrutinib and CD19 CAR T Cells Restore the Number of Granulocytic Myeloid Derived Suppressor Cells in CLL-Bearing Mice.'

See more updates from this year’s ASH Annual Meeting and Exposition at #ASH19

Category: Conferences, General News


Search News


No comments yet

Add a comment

Your email address will not be published. Required fields are marked *